NLRP3 and atherosclerosis: Subsequently, treatment with colchicine, a drug previously shown to inhibit NLRP3, has been associated with a significant reduction of ischemic cardiovascular events.9 Many other specific NLRP3 inhibitors and inhibitors of other inflammasomes, which are shown to be involved in atherosclerosis, are in development.